Sunday, March 7th | 23 Adar 5781

Subscribe
August 19, 2020 4:12 pm

UAE’s G42 Healthcare and Israel’s NanoScent Sign MOU for COVID-19 Screening Test

avatar by Reuters and Algemeiner Staff

A woman rinses her mouth with a saline wash, at Sheba Medical Center at Tel Hashomer, in Ramat Gan, Israel, Aug. 13, 2020. Photo: Reuters / Ammar Awad.

Abu Dhabi’s G42 Healthcare has signed a preliminary agreement with Israel‘s NanoScent to develop, distribute, and manufacture a test that detects COVID-19 from exhaled air, the UAE state news agency WAM reported on Wednesday.

The memorandum of understanding (MOU) is the latest in a series of deals between Emirati and Israeli companies to tackle the pandemic, something the two countries said was a priority in a joint statement last Thursday when announcing a normalizing of diplomatic relations.

The test, called Scent Check, will provide results in 30 to 60 seconds, WAM said, adding G42 will undergo thousands of tests for the device in coming weeks.

“The non-invasiveness and the rapidity of results give Scent Check the potential to transform the diagnostics industry globally,” WAM said. The device captures exhaled air, and analyzes the “volatile organic compounds” present using machine learning, the statement said.

Related coverage

March 5, 2021 10:05 am
0

Are Israel’s New $100 Million Helicopters Allergic to Dust?

CTech - A week after Israel's Minister of Defense Benny Gantz approved the Air Force's recommendation to purchase from the...

On Saturday, the Emirati APEX National Investment company signed a “strategic commercial agreement” with Israel‘s Tera Group to cooperate on coronavirus-related research and development, including a testing device.

Israel‘s Pluristem said on Monday it would partner with Abu Dhabi Stem Cells Center (ADSCC) to develop therapies for diseases including COVID-19.

Prior to the normalization deal, two state-owned Israeli defense contractors in July announced partnerships with G42 to develop technologies to help fight the coronavirus.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.